The Safety, Immunogenicity, and Immunopersistence of Hepatitis A Vaccine in HBs-Ag-Positive Participants: A Retrospective Study
ObjectivesTo compare the safety, immunogenicity, and immune persistence of hepatitis A (HA) vaccines between HBs-Ag-positive and -negative participants.Method9000 participants were enrolled in the phase IV study of live attenuated HA (HA-L) or inactivated HA (HA-I) vaccines. The HBs-Ag-positive subj...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-06-01
|
| Series: | Frontiers in Cellular and Infection Microbiology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcimb.2021.672221/full |
| _version_ | 1819259906692218880 |
|---|---|
| author | Xiaodan Wang Xiaodan Wang Xiaodan Wang Jia Luo Jia Luo Jia Luo Fubao Ma Guodong Kang Zhengrong Ding Yue Pan Yue Pan Yue Pan Yujiao Zhao Yujiao Zhao Yujiao Zhao Junying Chen Junying Chen Junying Chen Kai Feng Kai Feng Kai Feng Lingmei Yan Lingmei Yan Lingmei Yan Juan Zhang Juan Zhang Juan Zhang Juan Zhang Linhao Li Linhao Li Linhao Li Linhao Li Qiangping Lan Qiangping Lan Qiangping Lan Daiying Li Daiying Li Daiying Li Xiaolei Yang Xiaolei Yang Xiaolei Yang Guoliang Li Guoliang Li Guoliang Li Jingsi Yang Jingsi Yang Jingsi Yang Qiangming Sun Qiangming Sun Qiangming Sun |
| author_facet | Xiaodan Wang Xiaodan Wang Xiaodan Wang Jia Luo Jia Luo Jia Luo Fubao Ma Guodong Kang Zhengrong Ding Yue Pan Yue Pan Yue Pan Yujiao Zhao Yujiao Zhao Yujiao Zhao Junying Chen Junying Chen Junying Chen Kai Feng Kai Feng Kai Feng Lingmei Yan Lingmei Yan Lingmei Yan Juan Zhang Juan Zhang Juan Zhang Juan Zhang Linhao Li Linhao Li Linhao Li Linhao Li Qiangping Lan Qiangping Lan Qiangping Lan Daiying Li Daiying Li Daiying Li Xiaolei Yang Xiaolei Yang Xiaolei Yang Guoliang Li Guoliang Li Guoliang Li Jingsi Yang Jingsi Yang Jingsi Yang Qiangming Sun Qiangming Sun Qiangming Sun |
| author_sort | Xiaodan Wang |
| collection | DOAJ |
| description | ObjectivesTo compare the safety, immunogenicity, and immune persistence of hepatitis A (HA) vaccines between HBs-Ag-positive and -negative participants.Method9000 participants were enrolled in the phase IV study of live attenuated HA (HA-L) or inactivated HA (HA-I) vaccines. The HBs-Ag-positive subjects were detected and became an independent observation group. Adverse reactions (ARs), geometric mean concentrations (GMCs) and seroconversion rates (SRs) of the vaccines were analyzed at five time points until three years after vaccination. Results: 120 HBs-Ag-positive subjects were screened out, only 1 participant had grade 1 experienced ARs after HA-L injection. Except the time point of two years, the SRs of HBs-Ag-positive group were 100% for both vaccines. The GMCs were not statistically different between HBs-Ag-positive and -negative groups after the HA-L vaccination. The logarithmically transformed GMCs for HBs-Ag-positive and -negative groups were 3.21 mIU/mL (95% CI, 2.03-4.39 mIU/mL) and 2.95 mIU/mL (95% CI, 2.88-3.02 mIU/mL) 28 days after the HA-L vaccination, respectively.ConclusionsBoth HA-L and HA-I vaccines were safe for HBs-Ag-positive participants and may provide an excellent long-term protection against HAV in this study. The results indicated that people positive or negative for HBs-Ag can receive both HA-L and HA-I vaccines (ClinicalTrials.gov number, NCT02601040). |
| first_indexed | 2024-12-23T19:17:27Z |
| format | Article |
| id | doaj.art-3d0aac2d02ff42f089f46607ac7cf2d9 |
| institution | Directory Open Access Journal |
| issn | 2235-2988 |
| language | English |
| last_indexed | 2024-12-23T19:17:27Z |
| publishDate | 2021-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cellular and Infection Microbiology |
| spelling | doaj.art-3d0aac2d02ff42f089f46607ac7cf2d92022-12-21T17:34:17ZengFrontiers Media S.A.Frontiers in Cellular and Infection Microbiology2235-29882021-06-011110.3389/fcimb.2021.672221672221The Safety, Immunogenicity, and Immunopersistence of Hepatitis A Vaccine in HBs-Ag-Positive Participants: A Retrospective StudyXiaodan Wang0Xiaodan Wang1Xiaodan Wang2Jia Luo3Jia Luo4Jia Luo5Fubao Ma6Guodong Kang7Zhengrong Ding8Yue Pan9Yue Pan10Yue Pan11Yujiao Zhao12Yujiao Zhao13Yujiao Zhao14Junying Chen15Junying Chen16Junying Chen17Kai Feng18Kai Feng19Kai Feng20Lingmei Yan21Lingmei Yan22Lingmei Yan23Juan Zhang24Juan Zhang25Juan Zhang26Juan Zhang27Linhao Li28Linhao Li29Linhao Li30Linhao Li31Qiangping Lan32Qiangping Lan33Qiangping Lan34Daiying Li35Daiying Li36Daiying Li37Xiaolei Yang38Xiaolei Yang39Xiaolei Yang40Guoliang Li41Guoliang Li42Guoliang Li43Jingsi Yang44Jingsi Yang45Jingsi Yang46Qiangming Sun47Qiangming Sun48Qiangming Sun49Institute of Medical Biology, Chinese Academy of Medical Sciences, and Peking Union Medical College, Kunming, ChinaYunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, ChinaYunnan Provincial Key Laboratory of Vector-borne Diseases Control and Research, Kunming, ChinaInstitute of Medical Biology, Chinese Academy of Medical Sciences, and Peking Union Medical College, Kunming, ChinaYunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, ChinaYunnan Provincial Key Laboratory of Vector-borne Diseases Control and Research, Kunming, ChinaVaccines and Immunization Department, Jiangsu Provincial Center of Disease Control and Prevention, Nanjing, ChinaVaccines and Immunization Department, Jiangsu Provincial Center of Disease Control and Prevention, Nanjing, ChinaVaccines and Immunization Department, Yunnan Provincial Center of Disease Control and Prevention, Kunming, ChinaInstitute of Medical Biology, Chinese Academy of Medical Sciences, and Peking Union Medical College, Kunming, ChinaYunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, ChinaYunnan Provincial Key Laboratory of Vector-borne Diseases Control and Research, Kunming, ChinaInstitute of Medical Biology, Chinese Academy of Medical Sciences, and Peking Union Medical College, Kunming, ChinaYunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, ChinaYunnan Provincial Key Laboratory of Vector-borne Diseases Control and Research, Kunming, ChinaInstitute of Medical Biology, Chinese Academy of Medical Sciences, and Peking Union Medical College, Kunming, ChinaYunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, ChinaYunnan Provincial Key Laboratory of Vector-borne Diseases Control and Research, Kunming, ChinaInstitute of Medical Biology, Chinese Academy of Medical Sciences, and Peking Union Medical College, Kunming, ChinaYunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, ChinaYunnan Provincial Key Laboratory of Vector-borne Diseases Control and Research, Kunming, ChinaInstitute of Medical Biology, Chinese Academy of Medical Sciences, and Peking Union Medical College, Kunming, ChinaYunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, ChinaYunnan Provincial Key Laboratory of Vector-borne Diseases Control and Research, Kunming, ChinaInstitute of Medical Biology, Chinese Academy of Medical Sciences, and Peking Union Medical College, Kunming, ChinaYunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, ChinaYunnan Provincial Key Laboratory of Vector-borne Diseases Control and Research, Kunming, ChinaSchool of Basic Medicine, Kunming Medical University, Kunming, ChinaInstitute of Medical Biology, Chinese Academy of Medical Sciences, and Peking Union Medical College, Kunming, ChinaYunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, ChinaYunnan Provincial Key Laboratory of Vector-borne Diseases Control and Research, Kunming, ChinaSchool of Basic Medicine, Kunming Medical University, Kunming, ChinaInstitute of Medical Biology, Chinese Academy of Medical Sciences, and Peking Union Medical College, Kunming, ChinaYunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, ChinaYunnan Provincial Key Laboratory of Vector-borne Diseases Control and Research, Kunming, ChinaInstitute of Medical Biology, Chinese Academy of Medical Sciences, and Peking Union Medical College, Kunming, ChinaYunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, ChinaYunnan Provincial Key Laboratory of Vector-borne Diseases Control and Research, Kunming, ChinaInstitute of Medical Biology, Chinese Academy of Medical Sciences, and Peking Union Medical College, Kunming, ChinaYunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, ChinaYunnan Provincial Key Laboratory of Vector-borne Diseases Control and Research, Kunming, ChinaInstitute of Medical Biology, Chinese Academy of Medical Sciences, and Peking Union Medical College, Kunming, ChinaYunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, ChinaYunnan Provincial Key Laboratory of Vector-borne Diseases Control and Research, Kunming, ChinaInstitute of Medical Biology, Chinese Academy of Medical Sciences, and Peking Union Medical College, Kunming, ChinaYunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, ChinaYunnan Provincial Key Laboratory of Vector-borne Diseases Control and Research, Kunming, ChinaInstitute of Medical Biology, Chinese Academy of Medical Sciences, and Peking Union Medical College, Kunming, ChinaYunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, ChinaYunnan Provincial Key Laboratory of Vector-borne Diseases Control and Research, Kunming, ChinaObjectivesTo compare the safety, immunogenicity, and immune persistence of hepatitis A (HA) vaccines between HBs-Ag-positive and -negative participants.Method9000 participants were enrolled in the phase IV study of live attenuated HA (HA-L) or inactivated HA (HA-I) vaccines. The HBs-Ag-positive subjects were detected and became an independent observation group. Adverse reactions (ARs), geometric mean concentrations (GMCs) and seroconversion rates (SRs) of the vaccines were analyzed at five time points until three years after vaccination. Results: 120 HBs-Ag-positive subjects were screened out, only 1 participant had grade 1 experienced ARs after HA-L injection. Except the time point of two years, the SRs of HBs-Ag-positive group were 100% for both vaccines. The GMCs were not statistically different between HBs-Ag-positive and -negative groups after the HA-L vaccination. The logarithmically transformed GMCs for HBs-Ag-positive and -negative groups were 3.21 mIU/mL (95% CI, 2.03-4.39 mIU/mL) and 2.95 mIU/mL (95% CI, 2.88-3.02 mIU/mL) 28 days after the HA-L vaccination, respectively.ConclusionsBoth HA-L and HA-I vaccines were safe for HBs-Ag-positive participants and may provide an excellent long-term protection against HAV in this study. The results indicated that people positive or negative for HBs-Ag can receive both HA-L and HA-I vaccines (ClinicalTrials.gov number, NCT02601040).https://www.frontiersin.org/articles/10.3389/fcimb.2021.672221/fullhepatitis A vaccinesimmunogenicityimmune persistencehepatitis B surface antigensafety |
| spellingShingle | Xiaodan Wang Xiaodan Wang Xiaodan Wang Jia Luo Jia Luo Jia Luo Fubao Ma Guodong Kang Zhengrong Ding Yue Pan Yue Pan Yue Pan Yujiao Zhao Yujiao Zhao Yujiao Zhao Junying Chen Junying Chen Junying Chen Kai Feng Kai Feng Kai Feng Lingmei Yan Lingmei Yan Lingmei Yan Juan Zhang Juan Zhang Juan Zhang Juan Zhang Linhao Li Linhao Li Linhao Li Linhao Li Qiangping Lan Qiangping Lan Qiangping Lan Daiying Li Daiying Li Daiying Li Xiaolei Yang Xiaolei Yang Xiaolei Yang Guoliang Li Guoliang Li Guoliang Li Jingsi Yang Jingsi Yang Jingsi Yang Qiangming Sun Qiangming Sun Qiangming Sun The Safety, Immunogenicity, and Immunopersistence of Hepatitis A Vaccine in HBs-Ag-Positive Participants: A Retrospective Study Frontiers in Cellular and Infection Microbiology hepatitis A vaccines immunogenicity immune persistence hepatitis B surface antigen safety |
| title | The Safety, Immunogenicity, and Immunopersistence of Hepatitis A Vaccine in HBs-Ag-Positive Participants: A Retrospective Study |
| title_full | The Safety, Immunogenicity, and Immunopersistence of Hepatitis A Vaccine in HBs-Ag-Positive Participants: A Retrospective Study |
| title_fullStr | The Safety, Immunogenicity, and Immunopersistence of Hepatitis A Vaccine in HBs-Ag-Positive Participants: A Retrospective Study |
| title_full_unstemmed | The Safety, Immunogenicity, and Immunopersistence of Hepatitis A Vaccine in HBs-Ag-Positive Participants: A Retrospective Study |
| title_short | The Safety, Immunogenicity, and Immunopersistence of Hepatitis A Vaccine in HBs-Ag-Positive Participants: A Retrospective Study |
| title_sort | safety immunogenicity and immunopersistence of hepatitis a vaccine in hbs ag positive participants a retrospective study |
| topic | hepatitis A vaccines immunogenicity immune persistence hepatitis B surface antigen safety |
| url | https://www.frontiersin.org/articles/10.3389/fcimb.2021.672221/full |
| work_keys_str_mv | AT xiaodanwang thesafetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT xiaodanwang thesafetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT xiaodanwang thesafetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT jialuo thesafetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT jialuo thesafetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT jialuo thesafetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT fubaoma thesafetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT guodongkang thesafetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT zhengrongding thesafetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT yuepan thesafetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT yuepan thesafetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT yuepan thesafetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT yujiaozhao thesafetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT yujiaozhao thesafetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT yujiaozhao thesafetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT junyingchen thesafetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT junyingchen thesafetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT junyingchen thesafetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT kaifeng thesafetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT kaifeng thesafetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT kaifeng thesafetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT lingmeiyan thesafetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT lingmeiyan thesafetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT lingmeiyan thesafetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT juanzhang thesafetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT juanzhang thesafetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT juanzhang thesafetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT juanzhang thesafetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT linhaoli thesafetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT linhaoli thesafetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT linhaoli thesafetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT linhaoli thesafetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT qiangpinglan thesafetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT qiangpinglan thesafetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT qiangpinglan thesafetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT daiyingli thesafetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT daiyingli thesafetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT daiyingli thesafetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT xiaoleiyang thesafetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT xiaoleiyang thesafetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT xiaoleiyang thesafetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT guoliangli thesafetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT guoliangli thesafetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT guoliangli thesafetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT jingsiyang thesafetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT jingsiyang thesafetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT jingsiyang thesafetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT qiangmingsun thesafetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT qiangmingsun thesafetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT qiangmingsun thesafetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT xiaodanwang safetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT xiaodanwang safetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT xiaodanwang safetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT jialuo safetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT jialuo safetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT jialuo safetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT fubaoma safetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT guodongkang safetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT zhengrongding safetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT yuepan safetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT yuepan safetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT yuepan safetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT yujiaozhao safetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT yujiaozhao safetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT yujiaozhao safetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT junyingchen safetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT junyingchen safetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT junyingchen safetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT kaifeng safetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT kaifeng safetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT kaifeng safetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT lingmeiyan safetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT lingmeiyan safetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT lingmeiyan safetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT juanzhang safetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT juanzhang safetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT juanzhang safetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT juanzhang safetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT linhaoli safetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT linhaoli safetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT linhaoli safetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT linhaoli safetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT qiangpinglan safetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT qiangpinglan safetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT qiangpinglan safetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT daiyingli safetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT daiyingli safetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT daiyingli safetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT xiaoleiyang safetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT xiaoleiyang safetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT xiaoleiyang safetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT guoliangli safetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT guoliangli safetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT guoliangli safetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT jingsiyang safetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT jingsiyang safetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT jingsiyang safetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT qiangmingsun safetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT qiangmingsun safetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy AT qiangmingsun safetyimmunogenicityandimmunopersistenceofhepatitisavaccineinhbsagpositiveparticipantsaretrospectivestudy |